Kornimate/medical-research-clean huggingface dataset:
inpatient enrollment of patient portal app

Conditions: Orthopedic Disorder

Summary: this study aims to determine if inpatient enrollment into a patient communication app improves clinic follow-up of orthopedic trauma patients and improves survey completion rates after orthopedic trauma.

follow-up in trauma is historically poor. as a result, outcomes from trauma are difficult to collect via surveys and are often significantly influenced by selection bias. patient interaction apps like patient gateway are thought to facilitate greater participant involvement and adherence to treatment regimens. the investigators will explore if inpatient enrollment into patient gateway would improve clinic follow-up rates. increasing follow-up rates could improve the quality of care delivered. in addition, self-administered survey questionnaires are an important data collection tool in clinical practice, public health research and epidemiology. however, survey completion rates are typically poor in orthopaedic trauma. with the evaluation of modern technology, electronic applications are being increasingly used in both hospital and personal settings. in outpatient clinics, questionnaires to measure outcomes and monitor quality of care are administered by staff members using hospital owned tablet devices. recently, applications to complete these surveys on personal devices have been developed. in a recent cochrane review on the comparison of self-administered survey questionnaire responses collected using mobile apps versus other methods it was concluded that there are no data available on response rates. the investigators will attempt to address this question. all patient gateway naïve patients aged 18 years or older able to consent for themselves and admitted to the hospital for an orthopedic condition with the need for outpatient follow-up will be invited to participate in this study. exclusion criteria will be patients unable to consent for themselves, inability to communicate in english, and no possession of a smartphone.

Eligibility criteria:
inclusion criteria: * admitted to the hospital for an orthopedic condition with the need for outpatient follow-up * able to consent for themselves exclusion criteria: * unable to consent for themselves * inability to communicate in english * no possession of a smartphone
dusa: cyclic pdt for the prevention of ak & nmsc in solid organ transplant recipients

Conditions: Skin Cancer; Non-melanoma Skin Cancer; Sun Damaged Skin; Actinic Keratosis

Summary: this is a pilot, phase 2, prospective, comparative study to evaluate the safety and efficacy of the combination of levulan® kerastick® for topical solution and blue light illumination using the blu-u® blue light photodynamic therapy illuminator (levulanpdt). the study hypothesis is that post solid organ transplantation patients, highly susceptible to non-melanoma skin cancer, can be treated safely and effectively through clinical cyclic application of pdt, lessening morbidity and possible mortality for this immunosuppressed patient population.


Eligibility criteria:
inclusion criteria: * received solid organ transplant * 3-24 months post-transplant (any number of transplant) * time interval of at least 6 days duration where complications such as rejection episodes, viral infections, surgical interventions and therapies with mono or polyclonal antibodies are ruled out by the transplant team. * no prior history of nmsc in the treatment fields * no ak/bowen's disease in the treatment fields within the last 3 months. * moderate to severe sun damage * be willing to forego other interventions in the treatment fields than the ones approved by the investigator that would interfere with the protocol or evaluation of the study medication exclusion criteria: * patients with fitzpatrick's scale skin type iv-vi * cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins * known sensitivity to any of the components of the levulan® kerastick® for topical solution * prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit * unable to return for follow-up visits and tests * any condition or situation which in the investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study

Keywords: photodynamic therapy prevention actinic keratosis skin cancer non-melanoma skin cancer sun damaged skin solid organ transplant pdt
16-week flexible vs. 8-week semaglutide titration

Conditions: Diabetes type2

Summary: semaglutide is a glucagon like peptide 1 (glp-1) receptor agonist recently approved in israel to improve glycemic control in patients with type 2 diabetes mellitus. semaglutide is currently administered as a weekly subcutaneous injection.treatment with semaglutide is associated with the occurrence of gastrointestinal adverse events (gi-aes) commonly observed during glp-1 receptor agonist treatment. the most common adverse reactions, reported in ≥5% of patients treated with semaglutide are nausea, vomiting, diarrhea, abdominal pain and constipation. in this trial we plan to explore the effect of a slower titration regimen of semaglutide vs. the current label-recommended dose escalation regimen on the occurrence of gi-aes.


Eligibility criteria:
inclusion criteria: * have personally signed and dated the informed consent form indicating that he/she has been informed of all pertinent aspects of the trial. * be willing and able to comply with the scheduled visits and other study procedures. * meet one of the following categories: 1. the subject is a male. 2. the subject is a female who is not of reproductive potential, defined as a female who either: (1) is postmenopausal (defined as at least 12 months with no menses in women ≥45 years of age); (2) has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; or (3) has a congenital or acquired condition that prevents childbearing. 3. the subject is a female who is of reproductive potential and agrees to avoid becoming pregnant: while receiving study drug and for 60 days after the last dose of study drug by complying with one of the following: (1) practice abstinence† from heterosexual activity or (2) use (or have her partner use) acceptable contraception during heterosexual activity. acceptable methods of contraception are‡: single method (one of the following is acceptable): * non-hormonal intrauterine device (iud) * vasectomy of a female subject's male partner combination method (requires use of two of the following): * diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide) * cervical cap with spermicide (nulliparous women only) * contraceptive sponge (nulliparous women only) * male condom or female condom (cannot be used together) exclusion criteria: * has a known contraindication to use of glp-1 agonists. * has been treated with a glp-1 agonist in the last 30 days. * has a history of type 1 diabetes mellitus * has a medical history of untreated active proliferative retinopathy. * has other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or blinded investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
hearing aid education and adaptation system

Conditions: Hearing Loss

Summary: this rct will have two arms: a control group that receives the standard of care from audiologists and an experimental group that receives both the standard of care and the at-home use of the tellyhealth intervention. subjects in each group will complete questionnaires at enrollment, mid-study and at the end of the study.

htm will develop the "tellyhealth (tm) system" that will provide education on hearing aid use and maintenance. htm will conduct a randomized controlled trial (rct) to quantify the benefits of tellyhealth to patients and audiologists including: reductions in hearing handicap, improved knowledge of hearing aid handling, use and communications strategies; and improved audiologist aftercare. the investigators will recruit 80 subjects (half in each group) and each subject will participate in the study for 8-12 weeks.

Eligibility criteria:
inclusion criteria: * speaks and reads english fluently * has mild (25-40 db) to severe (70-95 db) monaural sensorineural hearing loss * will be fitted with one or two hearing aids at the time of enrollment * owns a standard tv * has internet access at home * has sufficient corrected vision to watch videos and read text on the tv and mobile device * no signs of dementia exclusion criteria: * lives with person who has enrolled in the study

Keywords: hearing loss presbycusis aging teleaudiology
evaluating the impact of synthetic cooling agents in combustible cigarettes on smoking perceptions and use

Conditions: Cigarette Smoking-Related Carcinoma

Summary: this clinical trial evaluates the impact of synthetic cooling agents in combustible cigarettes on smoking perceptions and use. menthol, a natural chemical, is a cooling agent that increases nicotine dependence among smokers. menthol cigarettes largely contribute to the huge burden that smoking puts on public health. approximately 43% of adult smokers smoke menthol cigarettes. regulatory agencies have begun a ban on menthol. in response to the ban, the tobacco industry has introduced synthetic cooling agents as a flavorless replacement to provide the same cooling effects as menthol. information gained from this trial may help researchers determine how the addition of synthetic cooling agents changes the appeal, abuse liability potential, and respiratory toxicity profile of combustible cigarettes.

primary objectives: i. assess the content of synthetic cooling agents in newly introduced cooling agent non-menthol, menthol, and traditional non-menthol cigarettes. ii. assess the subjective effects and abuse liability of cooling agent non-menthol cigarettes. exploratory objective: i. examine acute changes to pulmonary health associated with cooling agent cigarette use. outline: participants are randomized to use 1 of 3 cigarette conditions at 3 different study visits. participants participate in ad libitum smoking sessions with either a non-menthol control, menthol, or synthetic cooling agent cigarette condition once weekly (qw) over 3 weeks on study. participants also participate in an ad libitum smoking session with either their usual brand cigarette or the study cigarette condition at the end of each study visit. participants also undergo nasal swab collection over 5-10 minutes and spirometry and airwave oscillometry testing over 5-10 minutes pre- and post-smoking session at each study visit.

Eligibility criteria:
inclusion criteria: * aged 21 - 29 years * established cigarette user * willing to provide informed consent and abstain from using tobacco products 12 hours prior to the three lab sessions * read and speak english exclusion criteria: * recently coronavirus disease 2019 positive (covid-19+) or a recent covid-19 hospitalization * self-reported unstable or significant psychiatric conditions * history of cardiac event or distress within the past 3 months * are currently pregnant, planning to become pregnant, or breastfeeding * currently attempting to quit using combustible tobacco products * have suffered from any serious lung disease or infection in the past 30 days
emergency department home blood pressure monitoring and bptru study

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the congruence of emergency department (ed) attendings' predictions of hypertension with results of home blood pressure monitoring.

evaluate the congruence of emergency department (ed) attendings' predictions of hypertension with results of home blood pressure monitoring \& evaluate reliability of ed measured elevated blood pressure compared to the bptru

Eligibility criteria:
inclusion criteria: * one elevated blood pressure greater than 120 systolic and/or 80 diastolic * bptru device blood pressure greater than 120 systolic and/or 80 diastolic while in ed exclusion criteria: * prior history of hypertension * currently on antihypertensives or receiving prescription on discharge * pregnancy * history of atrial fibrillation * dialysis patient * nursing home or rehabilitation center resident * admitted * moving out of the area in next 30 days * substance abuse * prisoner * presenting for psychiatric complaint requiring constant observation * inability to give informed consent (intoxicated, altered, non-english speaking) * presenting with symptoms of hypertensive emergency * inability to demonstrate adequate use of the home blood pressure device in the ed * arm circumference less than 9 inches or greater than 17 inches

Keywords: emergency medical services emergency care hypertension bptru blood pressure
histological/ immunohistological and molecularpathological types of epulides and central giant cell lesions of the jaws

Conditions: Epulis

Summary: this retrospective study will evaluate the patient collective of the division of oral surgery and orthodontics, department of dental medicine and oral health and of the division of cranio-maxillofacial surgery at the medical university graz concerning the frequency of epulis/giant cell lesion or underlying differential diagnoses and immunophenotypes as well as the resulting treatment methods and their success and compare these with international results

different histopathological differential diagnoses can underlay the clinical presentation of an epulis. often the immunophenotype of these lesions is of particular importance. this also holds for the the central giant cell lesion. this study will evaluate the patient collective of the division of oral surgery and orthodontics, department of dental medicine and oral health and of the division of cranio-maxillofacial surgery at the medical university graz concerning the frequency of epulis/giant cell lesion or underlying differential diagnoses and immunophenotypes as well as the resulting treatment methods and their success and compare these with international results. this is a retrospective study using electronic patient records, written records, operative reports of the division of oral surgery and orthodontics, department of dental medicine and oral health and of the division of cranio-maxillofacial surgery at the medical university graz in the period from 1986 to march 2018. it is intended to gather the data within 12 months and analyze statistically subsequently.

Eligibility criteria:
inclusion criteria: * existence of a medical history and a histopathological finding of the surgical specimen * patients treated in the outpatient clinic for diseases of oral mucosa of the division of oral surgery and orthodontics, department of dental medicine and oral health and of the division of cranio-maxillofacial surgery at the medical university graz between 1986 and march 2018 exclusion criteria: * absence of a medical history or a histopathological finding.
hfnc vs nasal cannula in mild chronic obstructive pulmonary disease exacerbation

Conditions: COPD Exacerbation

Summary: for aecopd patients, only 8% patients ventilated by noninvasive and invasive positive pressure ventilation. nasal cannula is the most common pattern of oxygen therapy in mild aecopd. as a low flow oxygen therapy, nasal cannula has many disadvantages.therefore, we design a randomized controlled trial(rct)to explore whether hfnc would be better than nasal cannula to prevent the aggravation of respiratory failure and endotracheal intubation in mild aecopd.

for aecopd patients, most of patients don't need respiratory support, only 8% patients ventilated by noninvasive and invasive positive pressure ventilation. nasal cannula is the most common pattern of oxygen therapy in mild aecopd. as a low flow oxygen therapy, nasal cannula has many disadvantages: discomfort, low humidity and unstable fraction of inspired oxygen(fio2) in inspiratory gas. therefore, we design a rct to explore whether hfnc would be better than nasal cannula to prevent the aggravation of respiratory failure and endotracheal intubation in mild aecopd.

Eligibility criteria:
inclusion criteria: * aecopd; ph≥7.35, paco2\>45 mmhg exclusion criteria: * need to be intubated immediately; refuse to engage in the study; severe organ dysfunction

Keywords: copd exacerbation high flow oxygen nasal cannula mild
diagnostic accuracy of emergency physician performed bedside ultrasound in suspected acute appendicitis

Conditions: Acute Abdomen; Acute Appendicitis

Summary: the aim of the study is to evaluate the diagnostic yield and accuracy of bedside emergency physician performed ultrasound in the diagnosis of acute appendicitis.

emergency physician (ep) performed bedside ultrasound is cost effective, repeatable and especially useful in the diagnosis of life treating conditions such as aortic dissection, traumatic bleedings. while abdominal pain is a common complaint in the emergency department and accurate diagnosis of its etiology may affect the patient's outcome, the accuracy and the diagnostic yield of bedside ep performed ultrasound is not well established. the diagnosis of a patient presented to emergency department with right lower abdominal pain is generally problematic and physician has to exclude acute surgical reasons such as acute appendicitis. in this study, patients who are suspicious to have acute appendicitis base on their clinical findings will be included. ep will record his diagnosis and then patient will undergo emergency physician performed ultrasound. after ultrasound ep will fill the study form according to us findings and record his diagnosis once again. at the end of the study the investigators evaluate and compare the radiology performed us reports and if there is operational biopsy results with the ep's pre- and post ultrasound diagnosis to estimate the diagnostic yield and accuracy of bedside emergency physician performed ultrasound in the diagnosis of acute appendicitis.

Eligibility criteria:
inclusion criteria: * patient presented with the complaint of right lower abdominal pain * suspected acute appendicitis exclusion criteria: * flank pain * previous appendectomy * pregnancy * unstable vital signs * frank peritonitis * us performed before ep's examination

Keywords: emergency ultrasound acute appendicitis bedside ultrasound
effect of cpap treatment on glycemic control in gestational diabetes: a pilot randomized-controlled trial

Conditions: Pregnancy; Sleep-disordered Breathing; Gestational Diabetes

Summary: clinical trial on effects of continuous positive airway pressure (cpap) on glucose levels in pregnant patients with sleep-disordered breathing and gestational diabetes

gestational diabetes (gdm), defined as glucose intolerance that is first recognized during pregnancy, is associated with adverse maternal and fetal outcomes. sleep-disordered breathing (sdb) is characterized by breathing pauses during sleep leading to recurrent arousals and intermittent hypoxia. the resulting increases in sympathetic drive, cortisol and inflammation have been shown to lead to glucose dysregulation. in that sdb is prevalent during pregnancy, sdb may represent a novel risk factor for gdm, as suggested by recent observational studies. no interventional studies evaluating the effects of sdb treatment on gdm outcomes have yet been published. general objective: to perform a pilot study to assess the feasibility of conducting a randomized-controlled trial using continuous positive airway pressure (cpap) to evaluate the effects of sdb treatment on maternal-fetal outcomes in gdm. primary aim of pilot study: 1) to assess cpap adherence in pregnant patients with gdm. secondary aims: 2) to assess recruitment and retention rates over \~2 months of treatment 3) to assess adequacy of nasal dilator strips as the control intervention 4) to measure maternal glucose levels to determine sample size calculations for a future large-scale multi-site randomized-controlled trial.

Eligibility criteria:
inclusion criteria: * pregnant women aged ≥ 18 y referred to the gdm clinic at the mcgill university health centre * \>20 weeks and \<34 weeks gestational age at time of recruitment * gestational diabetes * sleep-disordered breathing (sdb) exclusion criteria: * pre-gestational type 1 or type 2 diabetes * multiple pregnancy * conception by ivf * prior treatment for sdb * severe medical illness * severe sdb (ahi \>30) and epworth sleepiness scale \>15 or oxygen desaturation index \>30 or sustained hypoxia \< 80% * habitual sleep duration on average less than 5 hours/night (determined by actigraphy) * cigarette smoking, alcohol consumption or illicit drug use
effects of neuromodulation on brain electric activity of parkinson's disease patients

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is a neurodegenerative and progressive movement disorder, whose population incidence is increasing. it is characterized by motor symptoms such as tremor, stiffness and bradykinesia, and non-motor symptoms, highlighting the executive dysfunction that can be present from the early stages of the disease. these deficits increase the risk of falls and reduce functional independence. transcranial direct current stimulation (etcc) can be an attractive rehabilitation option in pd because it is a non-invasive and safe method that can modulate cortical excitability and improve motor and non-motor symptoms. one of the techniques to detect neurophysiological biomarkers associated with changes in the functional health of the brain and the effectiveness of this type of treatment is the analysis of microstates from the electroencephalogram (eeg). so, the objective of the present study is to investigate the effects of different assemblies of multifocal etcc on the electrical brain activity represented by the eeg microstates and clinical characteristics in patients with pd.

for this, a randomized, triple-blind clinical trial will be conducted with 60 people with pd, between 40 and 75 years old, regardless of sex, recruited from the reference centers in neurology and physiotherapy in joão pessoa-pb. participants will be randomized into three groups: group 1 - etcc over m1 + cpfdl; group 2 - etcc on m1 + apf; group 3 - etcc on m1. in each condition an initial baseline assessment (t0) will be performed after 16 treatment sessions (t1) and 30 days after the end of the protocol (follow-up assessment - t2). the evaluated outcomes will be: analysis of microstates and spectral analysis of frequencies by eeg; dual task capability with timed up and go (tug); executive function (stroop test and verbal fluency test); motor aspects of daily life (mds updrs ii). for all analyzes, the statistical software spss (spss inc, chicago il, usa) for windows, version 20.0, will be used and statistical significance considered at 5% (p ≤ 0.05).

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd, issued by a neurologist specializing in movement disorders; * disease staging between i and iii, according to the modified hoehn and yahr scale; * regular antiparkinsonian pharmacological treatment; * score higher than 24 or 18 (for participants with low education) in the mini -mental state examination healthy subjects inclusion criteria: * ages: 40 - 75 years * sex: all * subjects who do not have self-report of neurodegenerative disorders exclusion criteria: * diagnosis of atypical parkinsonism; * neurological comorbidities; * history of epilepsy, neurosurgery (including metal clip implantation) and pacemaker implantation; * dbs implantation - deep brain stimulation; * patients missing two consecutive protocol sessions. healthy subjects exclusion criteria: * history of epilepsy; * metallic implants in the head; * clinical evidence of brain injury.